文献速递胸部肿瘤头颈与中枢神经肿瘤

靶向S100A9-ALDH1A1-视黄酸信号通路抑制EGFR突变肺癌脑复发

Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

奥希替尼可延长EGFR突变肺癌患者无进展生存期,但患者仍出现致死性转移复发,常累及脑。研究利用转移模型发现,胞内S100A9高表达的癌细胞逃逸奥希替尼并启动脑复发;S100A9上调ALDH1A1并激活视黄酸信号通路。基因抑制S100A9、ALDH1A1或视黄酸受体,或使用泛RAR拮抗剂,可大幅减少脑转移;癌细胞S100A9表达与奥希替尼治疗患者较差的无进展生存期相关。

要点

  • 胞内S100A9高表达的EGFR突变肺癌细胞可逃逸奥希替尼并启动脑复发。
  • S100A9上调ALDH1A1并激活视黄酸信号通路驱动脑复发。
  • 基因抑制S100A9、ALDH1A1或RAR,或用泛RAR拮抗剂,可大幅减少脑转移。

核心结论

  • 研究识别出一条驱动脑复发的新型S100A9-ALDH1A1-视黄酸信号轴,可作为治疗靶点。
  • 泛RAR拮抗剂靶向该通路可阻止癌症进展并延长患者生存。

研究设计与样本

  • 研究使用EGFR突变肺癌转移模型。

主要发现

  • 胞内S100A9高表达的癌细胞逃逸奥希替尼并启动脑复发。
  • S100A9上调ALDH1A1表达并激活视黄酸信号通路。
  • 基因抑制癌细胞中S100A9、ALDH1A1或视黄酸受体,或使用泛RAR拮抗剂,大幅减少脑转移。
  • 癌细胞S100A9表达与奥希替尼治疗患者较差的无进展生存期相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung cancer, including those with brain metastases. However, despite striking initial responses, osimertinib-treated patients eventually develop lethal metastatic relapse, often to the brain. Although osimertinib-refractory brain relapse is a major clinical challenge, its underlying mechanisms remain poorly understood. Using metastatic models of EGFR-mutant lung cancer, we show that cancer cells expressing high intracellular S100A9 escape osimertinib and initiate brain relapses. Mechanistically, S100A9 upregulates ALDH1A1 expression and activates the retinoic acid (RA) signaling pathway in osimertinib-refractory cancer cells. We demonstrate that the genetic repression of S100A9, ALDH1A1, or RA receptors (RAR) in cancer cells, or treatment with a pan-RAR antagonist, dramatically reduces brain metastasis. Importantly, S100A9 expression in cancer cells correlates with poor PFS in osimertinib-treated patients. Our study, therefore, identifies a novel, therapeutically targetable S100A9-ALDH1A1-RA axis that drives brain relapse. SIGNIFICANCE: Treatment with the EGFR TKI osimertinib prolongs the survival of patients with EGFR-mutant lung cancer; however, patients develop metastatic relapses, often to the brain. We identified a novel intracellular S100A9-ALDH1A1-RA signaling pathway that drives lethal brain relapse and can be targeted by pan-RAR antagonists to prevent cancer progression and prolong patient survival. This article is highlighted in the In This Issue feature, p. 873.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Biswas AK, Han S, Tai Y, et al. Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer. Cancer Discov. 2022. PMID: 35078784. doi:10.1158/2159-8290.CD-21-0910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。